Jonsson Comprehensive Cancer Center
🇺🇸United States
Psychoeducation for Uveal Melanoma
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 108
- Registration Number
- NCT06075589
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 95
- Registration Number
- NCT06067269
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06064682
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06059690
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT06047509
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 800
- Registration Number
- NCT05978128
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Withdrawn
- Conditions
- Interventions
- Procedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineOther: Fludeoxyglucose F-18Other: ImmunotherapyProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT05950113
- Locations
- 🇺🇸
Melanie Ayala Ceja, Los Angeles, California, United States
Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer
Early Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05841706
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05775471
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT05720988
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Habtemariam,Bruck, Los Angeles, California, United States
© Copyright 2024. All Rights Reserved by MedPath